Terms: = Skin cancer AND SMO, Q99835, 6608, ENSG00000128602, SMOH, Gx AND Treatment
68 results:
1. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment.
Cantisani C; Musolff N; Longo C; Di Guardo A; Rovaldi E; Rossi G; Sasso F; Farnetani F; Rega F; Bánvölgyiv A; Azzella G; Paolino G; Pellacani G
J Eur Acad Dermatol Venereol; 2024 May; 38(5):967-973. PubMed ID: 38270330
[TBL] [Abstract] [Full Text] [Related]
2. [The molecular genetic aspects of basal cell carcinoma from the position of population health preservation].
Khabriev RU; Sadykova RN; Mingazova EN; Bespyatykh JA
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Sep; 31(5):946-950. PubMed ID: 37898882
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
[TBL] [Abstract] [Full Text] [Related]
4. Emerging Roles of Hedgehog Signaling in cancer Immunity.
Giammona A; Crivaro E; Stecca B
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674836
[TBL] [Abstract] [Full Text] [Related]
5. Analysis of residual disease in periocular basal cell carcinoma following hedgehog pathway inhibition: Follow up to the VISORB trial.
Unsworth SP; Tingle CF; Heisel CJ; Eton EA; Andrews CA; Chan MP; Bresler SC; Kahana A
PLoS One; 2022; 17(12):e0265212. PubMed ID: 36455049
[TBL] [Abstract] [Full Text] [Related]
6. Novel Approaches in Non-Melanoma skin cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
[TBL] [Abstract] [Full Text] [Related]
7. skin cancer biology and barriers to treatment: Recent applications of polymeric micro/nanostructures.
Khan NH; Mir M; Qian L; Baloch M; Ali Khan MF; Rehman AU; Ngowi EE; Wu DD; Ji XY
J Adv Res; 2022 Feb; 36():223-247. PubMed ID: 35127174
[TBL] [Abstract] [Full Text] [Related]
8. GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients.
Dunjic M; Lukic N; Djordjevic B; Uzelac B; Ostojic N; Supic G
Melanoma Res; 2022 Feb; 32(1):11-17. PubMed ID: 34939981
[TBL] [Abstract] [Full Text] [Related]
9. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database.
Bassompierre A; Dalac S; Dreno B; Neidhardt EM; Maubec E; Capelle C; Andre F; Behal H; Dziwniel V; Bens G; Leccia MT; Meyer N; Granel-Brocard F; Beylot-Barry M; Dereure O; Basset-Seguin N; Mortier L
ESMO Open; 2021 Dec; 6(6):100284. PubMed ID: 34689002
[TBL] [Abstract] [Full Text] [Related]
10. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.
Kahana A; Unsworth SP; Andrews CA; Chan MP; Bresler SC; Bichakjian CK; Durham AB; Demirci H; Elner VM; Nelson CC; Kim DS; Joseph SS; Swiecicki PL; Worden FP
Oncologist; 2021 Jul; 26(7):e1240-e1249. PubMed ID: 33988881
[TBL] [Abstract] [Full Text] [Related]
11. Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma.
Pietrobono S; Gaudio E; Gagliardi S; Zitani M; Carrassa L; Migliorini F; Petricci E; Manetti F; Makukhin N; Bond AG; Paradise BD; Ciulli A; Fernandez-Zapico ME; Bertoni F; Stecca B
Oncogene; 2021 Jun; 40(22):3799-3814. PubMed ID: 33958721
[TBL] [Abstract] [Full Text] [Related]
12. Expert opinion on sonidegib efficacy, safety and tolerability.
Villani A; Fabbrocini G; Costa C; Ocampo-Garza SS; Lallas A; Scalvenzi M
Expert Opin Drug Saf; 2021 Aug; 20(8):877-882. PubMed ID: 33888008
[No Abstract] [Full Text] [Related]
13. MTOR promotes basal cell carcinoma growth through atypical PKC.
Chow RY; Levee TM; Kaur G; Cedeno DP; Doan LT; Atwood SX
Exp Dermatol; 2021 Mar; 30(3):358-366. PubMed ID: 33617094
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Biology of Basal and Squamous Cell Carcinomas.
Boeckmann L; Martens MC; Emmert S
Adv Exp Med Biol; 2020; 1268():171-191. PubMed ID: 32918219
[TBL] [Abstract] [Full Text] [Related]
15. Current Research in Melanoma and Aggressive Nonmelanoma skin cancer.
Wilken R; Criscito M; Pavlick AC; Stevenson ML; Carucci JA
Facial Plast Surg; 2020 Apr; 36(2):200-210. PubMed ID: 32413929
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities.
Spallone G; Sollena P; Ventura A; Fargnoli MC; Gutierrez C; Piccerillo A; Tambone S; Bianchi L; Peris K
Dermatol Ther; 2019 Nov; 32(6):e13108. PubMed ID: 31606940
[TBL] [Abstract] [Full Text] [Related]
17. Hedgehog Pathway Inhibition for the treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract] [Full Text] [Related]
18. smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects.
Bánvölgyi A; Anker P; Lőrincz K; Kiss N; Márton D; Fésűs L; Gyöngyösi N; Wikonkál N
J Dermatolog Treat; 2020 Jun; 31(4):387-398. PubMed ID: 31039644
[No Abstract] [Full Text] [Related]
19. miR-370 inhibits the angiogenic activity of endothelial cells by targeting smoothened (smo) and bone morphogenetic protein (BMP)-2.
Gu Y; Becker V; Zhao Y; Menger MD; Laschke MW
FASEB J; 2019 Jun; 33(6):7213-7224. PubMed ID: 30865837
[TBL] [Abstract] [Full Text] [Related]
20. Diagnosis and Management of Basal Cell Carcinoma.
Tanese K
Curr Treat Options Oncol; 2019 Feb; 20(2):13. PubMed ID: 30741348
[TBL] [Abstract] [Full Text] [Related]
[Next]
